Trade ImmuCell - ICCC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.17 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024818% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002596% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.56 |
| Open | 3.55 |
| 1-Year Change | -24.31% |
| Day's Range | 3.55 - 3.64 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 29, 2024 | 3.56 | 0.00 | 0.00% | 3.56 | 3.56 | 3.56 |
| Oct 28, 2024 | 3.56 | 0.00 | 0.00% | 3.56 | 3.56 | 3.56 |
| Oct 25, 2024 | 3.56 | 0.01 | 0.28% | 3.55 | 3.60 | 3.50 |
| Oct 24, 2024 | 3.56 | 0.01 | 0.28% | 3.55 | 3.65 | 3.55 |
| Oct 23, 2024 | 3.61 | 0.06 | 1.69% | 3.55 | 3.62 | 3.55 |
| Oct 22, 2024 | 3.59 | 0.05 | 1.41% | 3.54 | 3.64 | 3.50 |
| Oct 21, 2024 | 3.54 | -0.04 | -1.12% | 3.58 | 3.64 | 3.54 |
| Oct 18, 2024 | 3.61 | 0.02 | 0.56% | 3.59 | 3.62 | 3.54 |
| Oct 17, 2024 | 3.59 | 0.08 | 2.28% | 3.51 | 3.59 | 3.49 |
| Oct 16, 2024 | 3.52 | 0.01 | 0.28% | 3.51 | 3.60 | 3.46 |
| Oct 15, 2024 | 3.53 | -0.01 | -0.28% | 3.54 | 3.55 | 3.50 |
| Oct 14, 2024 | 3.55 | -0.08 | -2.20% | 3.63 | 3.63 | 3.54 |
| Oct 11, 2024 | 3.60 | -0.03 | -0.83% | 3.63 | 3.66 | 3.54 |
| Oct 10, 2024 | 3.63 | 0.08 | 2.25% | 3.55 | 3.70 | 3.54 |
| Oct 9, 2024 | 3.63 | -0.02 | -0.55% | 3.65 | 3.66 | 3.42 |
| Oct 8, 2024 | 3.65 | 0.06 | 1.67% | 3.59 | 3.81 | 3.59 |
| Oct 7, 2024 | 3.69 | 0.07 | 1.93% | 3.62 | 3.69 | 3.62 |
| Oct 4, 2024 | 3.60 | -0.04 | -1.10% | 3.64 | 3.76 | 3.59 |
| Oct 3, 2024 | 3.64 | -0.10 | -2.67% | 3.74 | 3.74 | 3.49 |
| Oct 2, 2024 | 3.60 | -0.05 | -1.37% | 3.65 | 3.67 | 3.49 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ImmuCell Company profile
About ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ImmuCell Corporation revenues increased 19% to $13.8M. Net loss decreased 87% to $152K. Revenues reflect First Defense® product line segment increase of 44% to $9.5M, Other animal health segment increase of 83% to $186K, United States segment increase of 18% to $12.2M, Others segment increase of 28% to $1.6M.
Equity composition
Common Stock $.10 Par, 12/10, 8M auth., 3,261,148 issd., less 287,496 shs. in Treas. @ $635K. Insiders own 26.70%. PO 5/87, 966,000 Units (100 Common + 5 Warrants) @ $7/Unit by Stuart James. 7/90, 1-for-100 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
56 Evergreen Drive
PORTLAND
MAINE 04103
US
News
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024
Gold markets to trade
Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.
08:00, 21 October 2024
US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024
ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024
Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024
Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024
S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com